期刊
MOLECULAR CELL
卷 59, 期 2, 页码 243-257出版社
CELL PRESS
DOI: 10.1016/j.molcel.2015.05.036
关键词
-
资金
- German Cancer Aid/Dr. Mildred Scheel Stiftung
- Wilhelm Sander Stiftung
- Deutsche Jose Carreras Stiftung
- Else Kroner-Fresenius Stiftung
- German Research Foundation
- Gottingen Graduate School of Neurosciences and Molecular Biosciences (GGNB)
- [SFB740]
Proteasome inhibition represents a promising strategy of cancer pharmacotherapy, but resistant tumor cells often emerge. Here we show that the micro-RNA-101 (miR-101) targets the proteasome maturation protein POMP, leading to impaired proteasome assembly and activity, and resulting in accumulation of p53 and cyclin-dependent kinase inhibitors, cell cycle arrest, and apoptosis. miR-101-resistant POMP restores proper turnover of proteasome substrates and re-enables tumor cell growth. In ER alpha-positive breast cancers, miR-101 and POMP levels are inversely correlated, and high miR-101 expression or low POMP expression associates with prolonged survival. Mechanistically, miR-101 expression or POMP knockdown attenuated estrogen-driven transcription. Finally, suppressing POMP is sufficient to overcome tumor cell resistance to the proteasome inhibitor bortezomib. Taken together, proteasome activity can not only be manipulated through drugs, but is also subject to endogenous regulation through miR-101, which targets proteasome biogenesis to control overall protein turnover and tumor cell proliferation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据